(120 days)
Not Found
No
The device description and performance studies focus on a standard enzyme immunoassay for detecting opiates in urine, with no mention of AI or ML techniques.
No
This device is an immunoassay for detecting opiates in urine, which is a diagnostic tool, not a therapeutic one. It provides analytical results but does not treat or alleviate a medical condition.
Yes
The device performs qualitative and semi-quantitative analysis of opiates in human urine, providing a preliminary analytical test result that contributes to a diagnosis, even if further confirmation is needed.
No
The device description clearly states it is a "ready-to-use, liquid reagent, homogeneous enzyme immunoassay" and describes a chemical process involving antibodies and enzyme activity measured spectrophotometrically. This indicates a physical, chemical-based assay, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states the assay is intended for "qualitative and semi-quantitative analyses of opiates in human urine." This involves testing a sample taken from the human body (urine) outside of the body (in vitro) to provide information about a medical condition or state (presence of opiates).
- Device Description: The description details a "homogeneous enzyme immunoassay" that uses "specific antibody" and measures "enzyme activity" in the urine sample. This is a typical description of an in vitro diagnostic test.
- Performance Studies: The document describes performance studies evaluating the device's ability to accurately detect opiates in urine samples, which is a key characteristic of an IVD.
- Predicate Device: The mention of a "Predicate Device" (K011150; DRI® DAU Opiate Assay) which is also an IVD, further supports the classification of this device as an IVD.
The definition of an IVD generally includes reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. This device fits this definition by providing information about the presence of opiates in a urine sample, which can be used in the diagnosis or management of drug use.
N/A
Intended Use / Indications for Use
The Opiate Enzyme Immunoassay is a homogeneous enzyme immunoassay with a 300 ng/mL cutoff. The assay is intended for use in the qualitative and semi-quantitative analyses of opiates in human urine.
The Opiate Enzyme Immunoassay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgement should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.
Product codes (comma separated list FDA assigned to the subject device)
DJG
Device Description
LZI’s Opiate Enzyme Immunoassay is a ready-to-use, liquid reagent, homogeneous enzyme immunoassay. The assay uses specific antibody that can detect opiates in human urine with minimal cross-reactivity to various, common prescription drugs and abused drugs.
The assay is based on competition between morphine labeled with glucose-6-phosphate dehydrogenase (G6PDH) enzyme, and free drug from the urine sample for a fixed amount of specific antibody. In the absence of free drug from the urine sample the specific antibody binds to the drug labeled with G6PDH enzyme causing a decrease in enzyme activity. The G6PDH enzyme activity is determined spectrophotometrically at 340 nm by measuring its ability to covert nicotinamide adenine dinucleotide (NAD) to NADH.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
human urine
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
LZI’s Opiate Enzyme Immunoassay was evaluated for several performance characteristics including precision, sensitivity, accuracy, analytical recovery, and specificity. All the studies showed acceptable results when compared to the predicate device.
Within Run Precision:
Qualitative:
- Negative: Mean Rate 291.6, SD 2.19, % CV 0.75
- 225 ng/mL: Mean Rate 374.4, SD 3.01, % CV 0.80
- 300 ng/mL: Mean Rate 399.8, SD 3.42, % CV 0.86
- 375 ng/mL: Mean Rate 421.8, SD 3.20, % CV 0.76
- 1000 ng/mL: Mean Rate 530.8, SD 5.17, % CV 0.97
Semi-quantitative: - 225 ng/mL: Mean Conc. 218.6, SD 5.96, % CV 2.73
- 300 ng/mL: Mean Conc. 298.0, SD 9.84, % CV 3.30
- 375 ng/mL: Mean Conc. 373.3, SD 11.18, % CV 3.00
Run-To-Run Precision (total precision):
Qualitative:
- Negative: Mean Rate 292.8, SD 1.81, % CV 0.62
- 225 ng/mL: Mean Rate 375.8, SD 3.61, % CV 0.96
- 300 ng/mL: Mean Rate 400.8, SD 3.34, % CV 0.83
- 375 ng/mL: Mean Rate 421.1, SD 2.87, % CV 0.68
- 1000 ng/mL: Mean Rate 528.6, SD 4.84, % CV 0.92
Semi-quantitative: - 225 ng/mL: Mean Conc. 223.8, SD 9.45, % CV 4.22
- 300 ng/mL: Mean Conc. 301.0, SD 9.15, % CV 3.04
- 375 ng/mL: Mean Conc. 377.8, SD 7.53, % CV 1.99
Sensitivity: 15 ng/mL
Accuracy: Vs. DRI® Opiate EIA (n = 216)
- Positive Samples: 97.1 % agreement
- Negative Samples: 93.8 % agreement
Analytical Recovery:
- Qualitative: 100 % accuracy on positive vs. negative tests
- Semi-quantitative: Quantitates within ±10% of the nominal concentration between 60ng/mL and 900 ng/mL.
- Average 97.7 % recovery at 225 ng/mL level (Cutoff - 25%)
- Average 96.7 % recovery at 375 ng/mL level (Cutoff + 25%)
Interference: Compounds tested are comparable to the predicate device. Results included in the specificity table.
Specificity: Comparable to the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity: 15 ng/mL
Accuracy: 97.1 % agreement for Positive Samples, 93.8 % agreement for Negative Samples.
Analytical Recovery Qualitative: 100 % accuracy on positive vs. negative tests.
Analytical Recovery Semi-quantitative: Quantitates within ±10% of the nominal concentration between 60ng/mL and 900 ng/mL.
Average 97.7 % recovery at 225 ng/mL level, Average 96.7 % recovery at 375 ng/mL level.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3650 Opiate test system.
(a)
Identification. An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.(b)
Classification. Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
JUN 0 4 2002
510(k) Summary of Safety and Effectiveness
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
Introduction
According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.
Submitter name, Address, and Contact
Lin-Zhi International, Inc. 2391 Zanker Road, Suite 340 San Jose, CA 95131-1124 Phone: (408) 944-0360 Fax: (408) 944-0359
Contact: Chiu Chin Chang, Ph.D. VP, R&D
Device Name and Classification
| Classification Name: | Opiate test system, Class II, DJG (91 Toxicology),
21CFR 862.3650 |
|----------------------|-------------------------------------------------------------------------------------|
| Common Name: | Homogeneous enzyme immunoassay for the determination
of opiates levels in urine. |
| Proprietary Name: | None |
Legally Marketed Predicate Device(s)
Lin-Zhi International, Inc.' Opiate Enzyme Immunoassay is substantially equivalent to the DRI® DAU Opiate Assay (By Microgenics Corp.), cleared under premarket notification K011150.
LZI's Opiate Enzyme Immunoassay is identical or similar to its predicate in terms of intended use, method principle, device components, and clinical performance.
Device Description
LZI's Opiate Enzyme Immunoassay is a ready-to-use, liquid reagent, homogeneous enzyme immunoassay. The assay uses specific antibody that can detect opiates in human urine with minimal cross-reactivity to various, common prescription drugs and abused drugs.
1
The assay is based on competition between morphine labeled with glucose-6-phosphate dehydrogenase (G6PDH) enzyme, and free drug from the urine sample for a fixed amount of specific antibody. In the absence of free drug from the urine sample the specific antibody binds to the drug labeled with G6PDH enzyme causing a decrease in enzyme activity. The G6PDH enzyme activity is determined spectrophotometrically at 340 nm by measuring its ability to covert nicotinamide adenine dinucleotide (NAD) to NADH.
Intended Use
The Opiate Enzyme Immunoassay is a homogeneous enzyme immunoassay with a 300 ng/mL cutoff. The assay is intended for use in the qualitative and semi-quantitative analyses of opiates in human urine.
Comparison to Predicate Device
LZI's Opiate Enzyme Immunoassay is substantially equivalent to other products in commercially distribution intended for similar use. Most notably it is substantially equivalent to the currently, commercially marketed DR1® Opiate Enzyme Immunoassay (K011150) by Microgenics Corporation.
The following table compares LZI's Opiate Enzyme Immunoassay with the predicate device, DRI® DAU Opiate Enzyme Immunoassay:
Similarities:
- . Both assays are for qualitative and semi-quantitative determination of opiates in human urine.
- Both assays use the same method principle, and device components. ●
- Both assays use 300 ng/mL as cutoff level per recommendations of The ● Substance Abuse and Metal Health Services Administration (SAMHSA).
Differences:
DRI® Opiate Enzyme Immunoassay can also be used as a 2000 ng/mL cutoff assay when different size of sample is used. Current LZI assay is for use as an assay with 300 ng/mL cutoff only.
2
(Comparison to Predicate Device, continued)
| Feature | Microgenics' DRI® Opiate EIA | LZI's Opiate EIA | ||||||
|---|---|---|---|---|---|---|---|---|
| Within Run Precision: | ||||||||
| Qualitative: | Mean Rate | SD | % CV | Mean Rate | SD | % CV | ||
| Negative | - | - | - | Negative | 291.6 | 2.19 | 0.75 | |
| 225 ng/mL | 374 | 2.2 | 0.6 | 225 ng/mL | 374.4 | 3.01 | 0.80 | |
| 300 ng/mL | 401 | 2.3 | 0.6 | 300 ng/mL | 399.8 | 3.42 | 0.86 | |
| 375 ng/mL | 421 | 2.4 | 0.6 | 375 ng/mL | 421.8 | 3.20 | 0.76 | |
| 1000 ng/mL | - | - | - | 1000 ng/mL | 530.8 | 5.17 | 0.97 | |
| Semi-quantitative: | Mean Conc. | SD | % CV | Mean Conc. | SD | % CV | ||
| 225 ng/mL | 226 | 6.0 | 2.7 | 225 ng/mL | 218.6 | 5.96 | 2.73 | |
| 300 ng/mL | 303 | 8.1 | 2.7 | 300 ng/mL | 298.0 | 9.84 | 3.30 | |
| 375 ng/mL | 379 | 15.1 | 4.0 | 375 ng/mL | 373.3 | 11.18 | 3.00 | |
| Run-To-Run Precision: | (total precision) | |||||||
| Qualitative: | Mean Rate | SD | % CV | Mean Rate | SD | % CV | ||
| Negative | - | - | - | Negative | 292.8 | 1.81 | 0.62 | |
| 225 ng/mL | 374 | 2.6 | 0.7 | 225 ng/mL | 375.8 | 3.61 | 0.96 | |
| 300 ng/mL | 401 | 3.2 | 0.8 | 300 ng/mL | 400.8 | 3.34 | 0.83 | |
| 375 ng/mL | 421 | 3.0 | 0.7 | 375 ng/mL | 421.1 | 2.87 | 0.68 | |
| 1000 ng/mL | - | - | - | 1000 ng/mL | 528.6 | 4.84 | 0.92 | |
| Semi-quantitative: | Mean Conc. | SD | % CV | Mean Conc. | SD | % CV | ||
| 225 ng/mL | 226 | 8.2 | 3.6 | 225 ng/mL | 223.8 | 9.45 | 4.22 | |
| 300 ng/mL | 303 | 9.4 | 3.1 | 300 ng/mL | 301.0 | 9.15 | 3.04 | |
| 375 ng/mL | 379 | 15.9 | 4.2 | 375 ng/mL | 377.8 | 7.53 | 1.99 | |
| Sensitivity: | 6 ng/mL | 15 ng/mL | ||||||
| Accuracy: | Vs. GC/MS | Vs. DRI® Opiate EIA (n = 216) | ||||||
| Positive Samples: 100 % agreement | 97.1 % agreement | |||||||
| Negative Samples: 90 % agreement | 93.8 % agreement | |||||||
| Analytical Recovery: | ||||||||
| Qualitative: No data available | 100 % accuracy on positive vs. negative tests | |||||||
| Semi-quantitative: No data available | Quantitates within ±10% of the nominal | |||||||
| concentration between 60ng/mL and 900 | ||||||||
| ng/mL. | ||||||||
| Average 97.7 % recovery at 225 ng/mL level | ||||||||
| (Cutoff - 25%) | ||||||||
| Average 96.7 % recovery at 375 ng/mL level | ||||||||
| (Cutoff + 25%) | ||||||||
| Interference: | See attached Microgenics' DRI® Opiate | |||||||
| EIA package insert | Compounds tested are comparable to the | |||||||
| predicate device. Results included in the | ||||||||
| specificity table. | ||||||||
| Specificity: | See attached Microgenics' DRI® Opiate | |||||||
| EIA package insert | Comparable to the predicate device. |
Performance Characteristics (Comparing the 300 ng/mL cutoff assay performance only)
3
Conclusion
LZI's Opiate Enzyme Immunoassay was evaluated for several performance characteristics including precision, sensitivity, accuracy, analytical recovery, and specificity. All the studies showed acceptable results when compared to the predicate device.
We trust the information provided in this Premarket Notification [510(k)] submission will support a determination of substantial equivalence of the LZI's Opaite Enzyme Immunoassay to other opiate test systems currently marketed in the United States.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo consists of a circular emblem with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the top half of the circle. Inside the circle is a stylized image of an eagle with three lines representing its wings and head. The eagle faces to the right.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
IUN 0 4 2002
Chiu Chin Chang, Ph.D. VP. R&D Lin-Zhi International, Inc. 2391 Zanker Road. Suite 340 San Jose, CA 95131-1124
Re: K020368
Trade/Device Name: Opiate Enzyme Immunoassay Regulation Number: 21 CFR 862.3650 Regulation Name: Opiate test system Regulatory Class: Class II Product Code: DJG Dated: April 24, 2002 Received: April 26, 2002
Dear Dr. Chang:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entifled. "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmaldsmamain.html".
Sincerely yours.
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Premarket Notification
Indications for Use Statement
510(k) Number (if known): _ KO20368
Device Name: Opiate Enzyme Immunoassay
Indications for Use:
The Opiate Enzyme Immunoassay is a homogeneous enzyme immunoassay with a 300 ng/mL cutoff. The assay is intended for use in the qualitative and semi-quantitative analyses of opiates in human urine.
The Opiate Enzyme Immunoassay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgement should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.
Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K020368
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)